Skip to main content

Table 1 Baseline demographic characteristics of the three groups of patients included in the analysis

From: Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase

Characteristic Responders (n = 23) Nonresponders (n = 43) Placebo (n = 21) P value
Age, years, mean (SD) 63.0 (14.1) 53.5 (14.0) 56.8 (10.5) 0.043
Sex, n 17 M, 6F 37 M, 6F 17 M, 4F 0.48
Disease duration, years, mean (SD) 17.0 (17.2) 15.1 (9.8) 14.9 (9.9) 0.97
sUA, mg/dl, mean (SD) 10.22 (1.76) 10.50 (1.62) 10.19 (1.82) 0.68
Number of tophi assessed 93 98 68 NC
Total tophus area, mm2, mean (SD) 585.8 (795.0) 661.5 (1298.7) 674.4 (1011.6) 0.32
Comorbidities, n
 Hypertension 16 30 17 0.60
 Dyslipidemia 14 17 10 0.25
 Diabetes mellitus 4 7 4 0.96
 Coronary artery disease 4 3 2 0.41
  1. Abbreviations: M Male, F Female, NC Not computed
  2. P value is for comparison of responders, nonresponders, and placebo